Business
IRIDEX develops laser consoles, probes and related devices used to treat glaucoma and retinal diseases.
IRIDEX grew ophthalmic-device revenue and narrowed operating losses, but negative cash flow and financing dependence leave the recovery incomplete.
The read at a glance✓ Audited against SEC data
- Growth — Revenue grew 8.2%OK
- Profitability — The net loss narrowed from $8.91M to $4.437MOK
- Cash flow — Free cash flow remained negative, with the outflow narrowing from $7.298M to $2.258MOK
- Margins — Operating margin expanded 1218 bps to -4.88%OK
- Accounting — Improving medical-device sales with financing riskWatch
- Insiders — 53 purchases and 0 salesOK
Where the revenue comes from
Fiscal 2026, as IRIDEX CORP reports it. History and quarterly detail are in the app.
- Retina$30.3M
- Cyclo G Six$13.8M
- Product And Service Other$8.6M
- Service$1K
Leadership changes
From IRIDEX CORP's own filings, the day they're filed.
- Kenneth E. Ludlum · Directors · departureeff. 2025-04-07
- Robert E. Grove · Directors · departureeff. 2025-04-02
- Patrick Mercer · Chief Executive Officer · appointmenteff. 2024-11-22
Latest filings
- 8-K · Company announcement2026-09-02
- 10-Q · Quarterly report2026-08-18
- 8-K · Company announcement2026-08-18
- 8-K · Company announcement2026-07-16
- 8-K · Company announcement2026-06-18
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about IRIDEX CORP, every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.